EMEA-001333-PIP02-13
Key facts
| Active substance |
Pradigastat
|
| Therapeutic area |
Endocrinology-Gynaecology-Fertility-Metabolism
|
| Decision number |
P/0120/2014
|
| PIP number |
EMEA-001333-PIP02-13
|
| Pharmaceutical form(s) |
Film-coated tablet
|
| Condition(s) / indication(s) |
Treatment of familial chylomicronaemia syndrome (type I hyperlipoproteinaemia
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Novartis Europharm Limited
|
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|